Reports
Publicerat: 2018-11-09 08:30:00
2018 THIRD QUARTER (Jul-Sep) FIRST NINE MONTHS 2018 (Jan-Sep)
FINANCIAL INFORMATION Costs – Costs for the third quarter were KSEK -3,540 (-2,969). Costs for the first nine months were KSEK -9,925 (-8,209). Result – Loss before tax for the third quarter was KSEK -3,461 (-2,970). Loss before tax for the first nine months was KSEK -9,808 (-8,243). Equity – PEPTONIC medical AB´s equity amounted to KSEK 60,384 (64,424) as of September 30, 2018, resulting in a solidity of 93 (91) percent. Share – Total numbers of shares in the company amounted to 86,028,600 (43,014,300) as of September 30, 2018. From the CEO During the third quarter many positive events took place in Peptonic. We launched the VagiVital webshop and kicked-off the sales, we received the first product order from Orion Pharma for their launch in Finland and we passed the Oriola quality control to become an approved supplier to a number of pharmacy chains in Sweden – just to mention a few. In the beginning of October, we informed the market that the on-line sales of VagiVital had developed very well, which indicates that the product has been well received. This trend has been sustained during the month of October. We continuously analyse information from the webshop and apply the new knowledge and experiences to improve the advertising and information flow to our customers. Beginning last week, VagiVital can now also be purchased on www.apohem.se . The dialogue with the pharmacy chains is underway in a positive tone and we think it’s a matter of time before VagiVital can be purchased via these channels, too. We have also initiated the preparations for launching VagiVital via our own webshops in Norway and Denmark. Our goal is to launch these webshops during the first quarter of 2019. In addition, we are entertaining discussions with a number of potential distributors outside the Nordic region. With focus on the USA, an analysis is underway to find out what documentation will be required for a registration (as a medical device under the 510k directive). In our opinion, a registration will considerably increase the probability of finding a good distributor and partner in this market. In addition to all these outwards directed activities, we are also actively searching for products to expand our product portfolio in women’s health. This is in line with Peptonic’s long term strategy to grow both organically and through acquisitions/collaborations in this rapidly growing market segment. A number of products are being evaluated at present. The financial result for the third quarter was as expected. Investment in marketing and sales have contributed to the increase in costs, whereas sales revenues are still rather small, however, with a positive trend. So, a lot is happening and at a fast pace in Peptoinc, and we have many exciting events to look forward to in the near future. We will of course keep our shareholders and the market informed. Johan Inborr CEO IMPORTANT EVENTS DURING THE PERIOD IMPORTANT EVENTS AFTER THE END OF THE PERIOD This interim report has not been reviewed by the Company’s auditors. The Board of Directors and the CEO certifies that the interim report gives a fair overview of the business, position and profit or loss of the Company. FINANCIAL CALENDER Year end report, 2017 February 27th 2019 Stockholm, November 9th, 2018 Hans von Celsing, Chairman of the Board Arne Ferstad, Board member Marianne Östlund, Board member Leni Ekendahl, Board member Johan Inborr, CEO For more information please contact: Johan Inborr, CEO Peptonic Medical AB. Phone: +46 708 853 893 Note: This document has been prepared in both Swedish and English. The Swedish version shall govern in case of differences between the two documents. The document contains certain statements about the Company’s operating environment and future performance. These statements should only be regarded as reflective of prevailing interpretations. No guarantees can be made that these statements are free from errors. COMPANY BRIEF Peptonic Medical is an innovative Swedish development company. Our vision is to offer safe and effective treatments for women suffering from vaginal atrophy during menopause and after. VagiVital® is a trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy. In July 2014, Peptonic Medical was listed on the AktieTorget stock exchange (www.spotlightstockmarket.com , ticker: PMED) in Stockholm. For more information: www.peptonicmedical.com About VagiVital® VagiVital® is a hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects. Peptonic Medical has launched VagiVital® as a non-prescription self-care product in 2018. For more information: www.vagivital.com
Net sales – Sales of products for the third quarter were KSEK 120 (0). Sales of products for the first nine months were KSEK 120 (0).
Financial position and liquidity – Liquid assets was KSEK 6,005 (11,115) as of September 30, 2018.
Organization – The average number of employees during the period was 2 (2). At the end of the period the number of employees was 2 (2).